July 18, 2011
CONTACT: Karen Kreeger
Penn Study Finds a Genetic Basis for Muscle Endurance in Animal Study
PHILADELPHIA — Researchers at the Perelman School of Medicine at the University of Pennsylvania have identified a gene for endurance, or more precisely, a negative regulator of it. Not having the gene relates to greater endurance in the knockout mice that were studied. The investigators also showed that the gene is linked to Olympic-level athletes in endurance sports such as swimming compared to athletes in sprint sports such as the 100-meter dash. The study appears online this week in the Journal of Clinical Investigation. The work has implications for improving muscle performance in disease states including metabolic disorders, obesity, and aging.
"We have shown that mice lacking the gene run six times longer than control mice and that the fatigable muscles of the mouse -- the fast muscle in the front of the leg -- have been reprogrammed and are now fatigue-resistant," explains senior author Tejvir S. Khurana, MD, PhD, professor of Physiology and member of the Pennsylvania Muscle Institute. "This has wide ramifications for various aspects of muscle biology ranging from athletics to treating muscle and metabolic diseases."
The gene codes for a protein called Interleukin-15 receptor-alpha (IL-15R-alpha), which acts alone or in conjunction with the IL-15 protein. IL-15R-alpha is important in the immune response, but it also has other functions. IL-15 and IL-15R-alpha have been implicated in muscle physiology, but the exact role in muscle function has not been defined.
"We found a previously unrecognized role for IL-15R-alpha in defining muscle function, and manipulation of this gene has the potential to improve muscle performance in disease states including metabolic disorders, obesity, and aging." says lead author Emidio E. Pistilli, PhD, who was a postdoctoral researcher at Penn and is now an assistant professor in the Division of Exercise Physiology at the West Virginia School of Medicine.
Slow Vs. Fast
In the IL-15R-alpha knockout mouse used in this study, fast muscles behave like slow muscles. These mice ran 6.3 times greater distances and had greater ambulatory activity than controls. Their fast muscles displayed fatigue-resistance and slower contractions compared to fast muscles in control mice.
They also showed that the loss of IL-15R-alpha induces a shift in how energy is burned in fast muscles, substantially increasing fatigue resistance and exercise capacity.
The molecular signature of the muscles in the knockout mice included a greater number of active transcription factors, which indicates more muscle fibers with more mitochondria, and the machinery to better process calcium since this chemical drives muscle contraction. Mitochondria are the energy storehouses of the cell.
Morphologically, the fast muscles had a greater number of muscle fibers, smaller fiber areas, and a greater number of nuclei per fiber. The alterations of physiological properties and increased resistance to fatigue in the fast muscles are consistent with a shift towards a slower, more oxidative muscle type in the knockout mice.
The study also found significant associations between the gene and elite endurance athletes and hence supports the possibility that these athletes had a genetic predisposition or advantage.
From these two lines of evidence, the researchers concluded that IL-15R-alpha plays a role in defining the function of fast skeletal muscles.
Importantly, the study demonstrates that muscles can be reprogrammed to perform much better at endurance sports and hence IL-15R-alpha manipulation is of great importance from an athletic doping standpoint as currently it is neither tested for nor do methods exist to detect its misuse by athletes. The investigators are working toward this.
This research identifies a "druggable target" that allows possible reprogramming of muscle function by increasing genes, proteins and pathways typically expressed in slow or fatigue-resistant muscle, similar to adaptations seen after endurance exercise. It is widely accepted that these types of adaptations would be beneficial or protect against obesity, diabetes and aging and may help ameliorate pathology in myopathies such as muscular dystrophy. Hence, say the researchers, the identification of this pathway should facilitate better understanding of these diseases and aid in the development of rational therapies drugs for these disorders.
From a translational research point of view the team will test the role IL-15R-alpha plays in obesity, diabetes, aging, and muscle diseases, as well as develop methods to harness the therapeutic potential of it for patients.
The research was funded by the National Institute of Arthritis and Musculoskelatal and Skin Diseases; the National Eye Institute; the National Institute on Aging; and the VA Puget Sound Health Care System.
In addition to Khurana and Pistilli, co-authors were from the Institute for Neuroscience and Muscle Research, The Children’s Hospital at Westmead, Sydney, New South Wales, Australia; the Australian Institute of Sport, Canberra, Australia; Geriatric Research, Education, and Clinical Center, VA Puget Sound Health Care System, Seattle; Division of Gerontology and Geriatric Medicine, Department of Medicine, University of Washington, Seattle; and the Division of Endocrinology, Diabetes, and Metabolism, Penn.
Penn Medicine is one of the world's leading academic medical centers, dedicated to the related missions of medical education, biomedical research, and excellence in patient care. Penn Medicine consists of the Raymond and Ruth Perelman School of Medicine at the University of Pennsylvania (founded in 1765 as the nation's first medical school) and the University of Pennsylvania Health System, which together form a $4.3 billion enterprise.
The Perelman School of Medicine has been ranked among the top five medical schools in the United States for the past 17 years, according to U.S. News & World Report's survey of research-oriented medical schools. The School is consistently among the nation's top recipients of funding from the National Institutes of Health, with $392 million awarded in the 2013 fiscal year.
The University of Pennsylvania Health System's patient care facilities include: The Hospital of the University of Pennsylvania -- recognized as one of the nation's top "Honor Roll" hospitals by U.S. News & World Report; Penn Presbyterian Medical Center; Chester County Hospital; Penn Wissahickon Hospice; and Pennsylvania Hospital -- the nation's first hospital, founded in 1751. Additional affiliated inpatient care facilities and services throughout the Philadelphia region include Chestnut Hill Hospital and Good Shepherd Penn Partners, a partnership between Good Shepherd Rehabilitation Network and Penn Medicine.
Penn Medicine is committed to improving lives and health through a variety of community-based programs and activities. In fiscal year 2013, Penn Medicine provided $814 million to benefit our community.